RATIONALE: There has been an upward trend in the utilization of digital interventions in healthcare settings. We conducted a targeted literature search to identify the impact of mobile applications on health outcomes for patients suffering from asthma. METHODS: A focused literature review was performed for published manuscripts (PubMed) and clinical trials (CT.gov) written about mobile interventions utilized to treat patients suffering from asthma from 2013-2018. The key terms ''asthma mobile apps'', ''asthma mobile'', and ''asthma digital interventions'' were used for our search. RESULTS: We reviewed a total of 64 studies including 23 published manuscripts, 34 clinical trials, and 7 systematic reviews. These studies assessed clinical (39.1%) and process outcomes (28.1%). Clinical outcomes included self-management of symptoms and medications (17.2%), asthma control (Asthma Control Test) scores (10.9%), adherence to medication (10.9%), asthma symptoms (3.1%), urgent health care and hospitalizations (3.1%), pulmonary function tests (1.6%) and asthma quality of life (1.6%). Process outcomes included platform usability (14.1%), patient satisfaction (9.4%), patient and/or provider self-efficacy (7.8%) , and healthcare provider-patient relationship (1.6%). 26 studies (40.6%) showed improvement of patient outcomes, 5 studies (7.8%) showed no difference and 28 studies (43.8%) had not published their results. CONCLUSIONS: Our data suggest that mobile health applications have positively affected health outcomes for patients suffering from asthma. However, this telehealth intervention can only reach a limited population (i.e. those that have access to the technology).To address this concern, further studies might focus on how telehealth affects health outcomes based on socioeconomic background.
medication (10.9%), asthma symptoms (3.1%), urgent health care and hospitalizations (3.1%), pulmonary function tests (1.6%) and asthma quality of life (1.6%). Process outcomes included platform usability (14.1%), patient satisfaction (9.4%), patient and/or provider self-efficacy (7.8%) , and healthcare provider-patient relationship (1.6%). 26 studies (40.6%) showed improvement of patient outcomes, 5 studies (7.8%) showed no difference and 28 studies (43.8%) had not published their results. CONCLUSIONS: Our data suggest that mobile health applications have positively affected health outcomes for patients suffering from asthma. However, this telehealth intervention can only reach a limited population (i.e. those that have access to the technology).To address this concern, further studies might focus on how telehealth affects health outcomes based on socioeconomic background. The Tueo program involves non-contact physiologic monitors, personalized analytics, and a smartphone application (app) to deliver targeted educational and clinical feedback that promotes asthma self-management. Whether the caregivers of asthmatic children find the app easy to use and access remains unknown. METHODS: Data relevant to usability was derived from a larger randomized controlled study designed to determine the impact of this platform on asthma control. This sub-analysis includes 77 participants who were in the intervention arm and responded to the final survey at the conclusion of the 16-week study. RESULTS: 83% reported a positive experience with the program. 86% reported the Tueo program helped in managing their child's asthma. 74% felt that the system was easy to use. Participants reported the alerts were among the most helpful program tools (55%) followed by the asthma coach (47%), education in the app (35%) and sensor data (33%). The likelihood to recommend on a scale of 0-10 had an average score of 8.5. Engagement, as measured via response rate to physiologic alerts was 88%. CONCLUSIONS: Overall, satisfaction with the program was high, which may contribute to long term engagement. The majority of participants felt the Tueo program was beneficial relative to asthma management and was easy to use. All program tools were reported as helpful with the alerts being most helpful. NorthShore University HealthSystem, Evanston, IL. RATIONALE: MM and AMR are HEDIS measures that may be useful for evaluating asthma control interventions to reduce the economic burden of asthma. This real-world study assessed healthcare resource use (HRU) and costs for PA patients stratified by attainment of MM and/or AMR. METHODS: This retrospective database analysis of claims linked to ambulatory electronic medical records included patients aged > _5 years with evidence of PA and continuous enrollment from May 2015 to April 2017. Patients attaining MM (proportion of days covered with asthma controller medication [ACM] > _75%) and/or AMR (ratio of ACM to total asthma medications > _0.5) were identified during a 1-year baseline period. HRU and costs during a 1-year follow-up period were compared between those attaining/not attaining MM (+MM/-MM) and attaining/not attaining AMR (+AMR/-AMR). RESULTS: Overall, 12,042/20,706 +MM/-MM patients and 24,388/8,360 +AMR/-AMR patients were identified. During the 1-year follow-up, the mean numbers of hospitalizations and emergency department visits were lower (p<0.0001) for +MM/+AMR versus -MM/-AMR (0.11/0.11 versus 0.14/0.19 and 0.38/0.45 versus 0.72/1.02, respectively). Overall, costs were lower for +AMR versus -AMR (total costs: $14,747/$17,804, p<0.0001; asthma-related costs: $2,545/$2,967, p50.001; total pharmacy costs: $6,000/$6,203, p50.3) but not for +MM versus -MM (total costs: $16,112/$15,187, p50.02; asthma-related costs: $2,623/$2,670, p50.7; total pharmacy costs: $6,976/$5,515, p<0.0001). CONCLUSIONS: Overall and asthma-specific costs were lower for patients attaining AMR, but not MM, mainly due to higher pharmacy costs for patients attaining MM. This suggests that MM attainment may not be as economically beneficial as AMR attainment. Further studies are needed to better understand this finding.
